A Randomized Controlled Trial of Colistin Combined with Sulbactam: 9 g per Day versus 12 g per Day in the Treatment of Extensively Drug-Resistant Acinetobacter baumannii Pneumonia: An Interim Analysis

Infectious Diseases Society of America Guidance on the Treatment of AmpC β-lactamase-Producing Enterobacterales, Carbapenem-Resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections

(2021) Pranita D Tamma et al.   CLINICAL INFECTIOUS DISEASES

Colistin heteroresistance in carbapenem-resistant Acinetobacter baumannii clinical isolates from a Thai university hospital

(2020) Khin Thet Thet et al.   WORLD JOURNAL OF MICROBIOLOGY & BIOTECHNOLOGY

Clinical Outcomes Of Colistin In Combination With Either 6-G Sulbactam Or Carbapenems For The Treatment Of Extensively Drug-Resistant Acinetobacter Baumannii Pneumonia With High MIC To Sulbactam, A Prospective Cohort Study

(2019) Chutchawan Ungthammakhun et al.   Infection and Drug Resistance

Population pharmacokinetics and pharmacodynamics modeling to optimize dosage regimens of sulbactam in critically ill patients with severe sepsis caused byAcinetobacterbaumannii

(2016) Sutep Jaruratanasirikul et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Dosing guidance for intravenous colistin in critically-ill patients

(2016) Roger L Nation et al.   CLINICAL INFECTIOUS DISEASES

Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society

(2016) Andre C. Kalil et al.   CLINICAL INFECTIOUS DISEASES

Molecular Mechanisms of Sulbactam Antibacterial Activity and Resistance Determinants in Acinetobacter baumannii

(2015) William F. Penwell et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Task force on management and prevention of Acinetobacter baumannii infections in the ICU

(2015) José Garnacho-Montero et al.   INTENSIVE CARE MEDICINE

Colistin alone or combined with sulbactam or carbapenem against A. baumannii in ventilator-associated pneumonia

(2015) Gul R. Yilmaz et al.   Journal of Infection in Developing Countries

Comparison of colistin–carbapenem, colistin–sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infections

(2014) A. Batirel et al.   EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES

Colistin-based treatment for extensively drug-resistant Acinetobacter baumannii pneumonia

(2014) Thana Khawcharoenporn et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Comparison of colistin and colistin/sulbactam for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia

(2013) G. Kalin et al.   INFECTION

In vitro effects of tigecycline in combination with colistin (polymyxin E) and sulbactam against multidrug-resistant Acinetobacter baumannii

(2013) Wentao Ni et al.   JOURNAL OF ANTIBIOTICS

White Paper: Recommendations on the Conduct of Superiority and Organism-Specific Clinical Trials of Antibacterial Agents for the Treatment of Infections Caused by Drug-Resistant Bacterial Pathogens

(2012)   CLINICAL INFECTIOUS DISEASES

Risk Factors for Mortality in Patients with Carbapenem-Resistant Acinetobacter baumannii Bacteremia: Impact of Appropriate Antimicrobial Therapy

(2012) Youn Jeong Kim et al.   JOURNAL OF KOREAN MEDICAL SCIENCE

Treatment ofAcinetobacterinfections

(2010) Argyris Michalopoulos et al.   EXPERT OPINION ON PHARMACOTHERAPY

Antimicrobial Treatment and Clinical Outcomes of Carbapenem-Resistant Acinetobacter baumannii Ventilator-Associated Pneumonia

(2010) Jeannie D. Chan et al.   JOURNAL OF INTENSIVE CARE MEDICINE

Antimicrobial-Resistant Pathogens Associated With Healthcare-Associated Infections: Annual Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006–2007

(2008) Alicia I. Hidron et al.   INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY

Potential for underdosing and emergence of resistance in Acinetobacter baumannii during treatment with colistin

(2008) M. D. David et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Ampicillin/sulbactam compared with polymyxins for the treatment of infections caused by carbapenem-resistant Acinetobacter spp.

(2008) M. S. Oliveira et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Efficacy and safety of high-dose ampicillin/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia

(2008) Alex P. Betrosian et al.   JOURNAL OF INFECTION

Colistin hetero-resistance in multidrug-resistant Acinetobacter baumannii clinical isolates from the Western Pacific region in the SENTRY antimicrobial surveillance programme

(2008) Wing Yau et al.   JOURNAL OF INFECTION

Current control and treatment of multidrug-resistant Acinetobacter baumannii infections

(2008) Drosos E Karageorgopoulos et al.   LANCET INFECTIOUS DISEASES